A Study of Safety, Pharmacokinetics, Pharmacodynamics of JNJ-61610588 in Participants With Advanced Cancer
An Open-label, First-in-Human, Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-61610588, a Fully Human IgG1 Kappa Anti-VISTA (V-domain Ig Suppressor of T-cell Activation) Monoclonal Antibody, in Subjects With Advanced Cancer
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States
-
-
Tennessee
-
Nashville, Tennessee, United States
-
-
Texas
-
Houston, Texas, United States
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- The participant has a solid tumor. Parts 2 and 3 are limited to participants with non-small cell lung cancer. Part 4 is limited to participants with small cell lung, head and neck, pancreatic, colorectal, and cervical cancers
- Tumor progression following at least one prior standard therapy
- The participant has a radiographically measurable tumor. Evaluable disease is acceptable for Part 1 only
- The participant is willing to consent to provide a tumor tissue sample (fresh biopsy) before (Parts 2 and 3) and after (Part 2 only) receiving the study drug
- The participant is able to carry out daily life activities without difficulty
- The participant does not have significant side effects from previous anti-cancer treatment
- The participant has adequate organ and blood cell counts
- Sexually active participants must use medically acceptable methods of contraception during the course of this study
Exclusion Criteria:
- The participant has a history of major surgery or treatment other cancer therapy within 2-6 weeks before starting the study
- The participant has an untreated brain tumor
- Current severe, uncontrolled systemic disease including an ongoing, active infection requiring treatment with antibiotics
- The participant has high blood pressure or diabetes that is not well-controlled with medication
- History of clinically significant heart problems
- History of severe side effects toimmunotherapy
- The participant is pregnant, breastfeeding, or planning to become pregnant or father a child
- Positive for Hepatitis B, Hepatitis C, or HIV
- The participant has received anticoagulant therapy with the exception of aspirin within 1 week of starting the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Part 1: Dose Escalation
Participants with advanced solid tumors will receive intravenous infusions of JNJ-61610588 until disease progression.
Dose escalation will continue until the maximum tolerated dose is reached.
|
Participants will receive intravenous infusions of JNJ-61610588 until disease progression.
|
|
Experimental: Part 2: Biomarker Evaluation
Participants with metastatic Non-small Cell Lung Cancer (NSCLC) will receive intravenous infusion of JNJ-61610588 at or below the recommended Phase 2 dose (RP2D) until disease progression.
|
Participants will receive intravenous infusions of JNJ-61610588 until disease progression.
|
|
Experimental: Part 3: Dose Expansion
Participants with metastatic Non-small Cell Lung Cancer (NSCLC) will receive intravenous infusion of JNJ-61610588 at the recommended Phase 2 dose (RP2D) until disease progression.
|
Participants will receive intravenous infusions of JNJ-61610588 until disease progression.
|
|
Experimental: Part 4: Dose Expansion
Participants with advanced solid tumors will receive intravenous infusion of JNJ-61610588 at the recommended Phase 2 dose (RP2D) until disease progression.
|
Participants will receive intravenous infusions of JNJ-61610588 until disease progression.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Frequency of Dose Limiting Toxicity (DLT)
Time Frame: Approximately 2.5 years
|
The Dose Limiting Toxicity (DLT) is based on adverse events and includes unacceptable hematologic toxicity, unacceptable non-hematologic toxicity of Grade 3 or higher, and treatment delay greater than 2 weeks.
|
Approximately 2.5 years
|
|
Number of Participants with Adverse Events (AEs) and Serious AEs
Time Frame: Approximately 2.5 years
|
An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.
A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
|
Approximately 2.5 years
|
|
Change From Baseline in Pharmacodynamic Blood Biomarkers- Total Blood Cell Counts
Time Frame: Approximately 2.5 years
|
Standard hematology laboratory tests will be used to evaluate total blood cell counts in blood samples collected pre- and posttreatment.
|
Approximately 2.5 years
|
|
Change From Baseline in Pharmacodynamic Blood Biomarkers- Markers of Monocyte Activation
Time Frame: Approximately 2.5 years
|
Flow cytometry will be used to evaluate markers of monocyte activation in blood samples collected pre- and posttreatment.
|
Approximately 2.5 years
|
|
Change From Baseline in Pharmacodynamic Blood Biomarkers- Markers of T Cell Activation
Time Frame: Approximately 2.5 years
|
Flow cytometry will be used to evaluate markers of T cell activation in blood samples collected pre- and posttreatment.
|
Approximately 2.5 years
|
|
Change From Baseline in Pharmacodynamic Tissue Biomarkers- Protein Expression of VISTA (V-domain Ig suppressor of T cell activation)
Time Frame: Approximately 2.5 years
|
Pre- and posttreatment tissue samples will be stained by immunohistochemistry for protein expression of VISTA.
|
Approximately 2.5 years
|
|
Change From Baseline in Pharmacodynamic Tissue Biomarkers- Markers Associated With Immune Infiltrate Including CD3, CD4, CD8, Forkhead box P3, CD68, and PD-L1.
Time Frame: Approximately 2.5 years
|
Pre- and posttreatment tissue samples will be stained by immunohistochemistry for markers associated with immune infiltrate including CD3, CD4, CD8, forkhead box P3, CD68, and PD-L1.
|
Approximately 2.5 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Maximum Serum Concentration (Cmax) of JNJ-61610588
Time Frame: Approximately 2.5 years
|
The Cmax is the maximum observed serum concentration of JNJ-61610588.
|
Approximately 2.5 years
|
|
Elimination Half-Life (t1/2)
Time Frame: Approximately 2.5 years
|
The elimination half-life (t1/2) is the time measured for the plasma concentration to decrease by 1 half to its original concentration.
It is associated with the terminal slope of the semi logarithmic drug concentration-time curve, and is calculated as 0.693/lambda(z).
|
Approximately 2.5 years
|
|
Area Under the Serum Concentration-Time Curve From t1 to t2 Time (AUC[t1-t2]) of JNJ-61610588
Time Frame: Approximately 2.5 years
|
The AUC(t1-t2) is the area under the serum JNJ-61610588 concentration-time curve from time t1 to t2.
|
Approximately 2.5 years
|
|
Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC[0-infinity])
Time Frame: Approximately 2.5 years
|
The AUC (0-infinity) is the area under the plasma concentration-time curve from time zero to infinite time, calculated as the sum of AUC(last) and C(last)/lambda(z); wherein AUC(last) is area under the plasma concentration-time curve from time zero to last quantifiable time, C(last) is the last observed quantifiable concentration, and lambda(z) is elimination rate constant.
|
Approximately 2.5 years
|
|
Number of Participants With Anti-JNJ-61610588 Antibodies
Time Frame: Approximately 2.5 years
|
Plasma levels of antibodies to JNJ-61610588 for evaluation of potential immunogenicity.
|
Approximately 2.5 years
|
|
Assessment of Anti-Tumor Activity, as Assessed by the Overall Response Rate (ORR)
Time Frame: Approximately 2.5 years
|
Anti-tumour activity as assessed by the ORR based on Response Evaluation Criteria in Solid Tumours (RECIST), version 1.1.
|
Approximately 2.5 years
|
|
Assessment of Anti-Tumor Activity, as Assessed by the Overall Response Rate (ORR)
Time Frame: Approximately 2.5 years
|
Anti-tumour activity as assessed by the ORR based on Immune-Related Response Criteria (irRC).
|
Approximately 2.5 years
|
|
Assessment of Anti-Tumor Activity, as Assessed by Duration of Response
Time Frame: Approximately 2.5 years
|
Anti-tumour activity as assessed by the duration of response.
|
Approximately 2.5 years
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CR108083
- 61610588LUC1001 (Other Identifier: Janssen Research & Development, LLC)
- 2016-001903-22 (EudraCT Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.